Free Trial
NASDAQ:CLNN

Clene Q3 2025 Earnings Results & Report

Clene logo
$4.04 +0.05 (+1.13%)
As of 12:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Clene missed analyst expectations on both earnings and revenue in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$0.85 versus the -$0.60 consensus estimate, while revenue of $15 thousand fell short of the $64 thousand estimate by $49 thousand.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
8:00 AM ET

Clene EPS Results

Actual EPS
-$0.85
Consensus EPS
-$0.60
Beat/Miss
Missed by -$0.25
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Clene Revenue Results

Actual Revenue
$15 thousand
Expected Revenue
$64 thousand
Beat/Miss
Missed by -$49.00 thousand
YoY Revenue Growth
N/A

Earnings Documents

Clene Q3 2025 Earnings FAQ

Clene (NASDAQ:CLNN) reported earnings of -$0.85 per share for Q3 2025, missing the consensus estimate of -$0.60. The report was announced on Thursday, November 13, 2025.

Clene reported revenue of $15 thousand for Q3 2025, against a consensus estimate of $64 thousand.

Clene Earnings Headlines

Research Analysts Set Expectations for Clene FY2026 Earnings
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.tc pixel
Clene (NASDAQ:CLNN) Stock Lifted to Hold by Wall Street Zen
Clene (CLNN) Expected to Announce Earnings on Thursday
See More Clene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Clene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clene and other key companies, straight to your email.

About Clene

Clene (NASDAQ:CLNN) is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. The company’s lead product candidate, CNM-Au8, is an investigational oral suspension containing catalytically active gold nanocrystals designed to support cellular energy production and reduce oxidative stress, with the goal of protecting and improving the function of nerve cells.

Clene has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and has also investigated its potential applications in other neurodegenerative disorders. CNM-Au8 remains an investigational therapy and is not approved for general commercial use.

Founded in 2013, Clene is headquartered in Salt Lake City, Utah, and conducts its research and clinical development activities primarily through U.S.-based programs, while working with research and clinical collaborators as appropriate. The company is led by Chief Executive Officer Robert Etherington and trades on the Nasdaq under the symbol CLNN.

View Clene Profile